CEO Viehbacher Confident In Biogen’s Portfolio, But Open To Additions
Q4 Revenue In Line, Guidance Below Consensus
As Biogen’s MS revenue continues its multi-year decline, the slow return to growth raises concerns about the company’s pipeline – but CEO Christopher Viehbacher said all is on track.
